CRL Charles River Laboratories International Inc.

Distinguished Industry Leaders Join Lineup for Inaugural Charles River World Congress on Animal Models in Drug Discovery & Development

Charles River Laboratories International, Inc. is proud to host the Inaugural Charles River World Congress on Animal Models in Drug Discovery & Development. Ranging from academia to the commercial sector, the World Congress on Animal Models speakers are each regarded as leaders in their respective fields.

At the Boston-based conference, being held on September 26-27, 2017, attendees will have access to keynotes and breakout sessions focused on the driving trends in reverse translational medicine.

The 25 keynote and breakout session speakers will present topics including: traditional and non-traditional animal models, novel in vitro and ex vivo approaches to disease modeling, and the application of technologies such as CRISPR/Cas9 gene editing, 3D bioprinting, the exploitation of the microbiome, and co-opting the immune system in the treatment of disease.

Notable Speakers

  • Jay Berzofsky, MD, PhD, Center for Cancer Research, National Cancer Institute, will discuss the translation of cancer vaccines from mouse models to clinical trials.
  • David Sabatini, MD, PhD, Whitehead Institute for Biomedical Research and Howard Hughes Medical Institute, will discuss genetic screens to study cancer biology. This year, Sabatini won the Lurie Prize in Biomedical Sciences from the Foundation for the National Institutes of Health.
  • Elazer Edelman, MD, PhD, Massachusetts Institute of Technology, Brigham and Women's Hospital and CBSET, will provide a historical perspective on reverse translational medicine. Edelman is a fellow of the National Academies of Medicine, of Engineering and of Inventors, and the American Academy of Arts and Sciences.
  • Jake Lusis, PhD, University of California, Los Angeles, will present on the complex interactions between metabolic and cardiovascular disease. Lusis was the 2015 Recipient of the Anitschkow Prize from the European Atherosclerosis Society.

The World Congress on Animal Models is a two-day scientific program presented by Charles River, in partnership with BioPharm America™. Attendees also receive full access to BioPharm America™ and all Biotech Week Boston events. To learn more and register, visit breakthroughs.criver.com and follow #CRLworldcon on social media.

Approved Quotes

  • “We are proud to welcome a distinguished group of speakers to Boston for the World Congress on Animal Models. With leaders from industry, the academic community, leading research hospitals and government agencies, our conference will provide a robust perspective on the state of translational medicine.” –Joseph Murphy, PhD, Program Committee Member for the World Congress on Animal Models
  • “The field of reverse translational medicine is important now more than ever. There is a critical need for continued, innovative drug discovery, and the bedside-to-bench approach provides an opportunity to repurpose valuable research. Bringing these leaders together will invigorate the conversation, and set the tone for years to come.” –Anjli Venkateswaran, PhD, Program Committee Member for the World Congress on Animal Models

About Charles River

Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit www.criver.com.

EN
29/08/2017

Underlying

Reports on Charles River Laboratories International Inc.

Charles River Laboratories Int'l, Inc.: Update to credit analysis

Charles River's credit profile reflects its strong and consistent free cash flow, offset by its sensitivity to R&D budgets of clients and research funding availability.

Moody's Ratings announces completion of a periodic review of ratings o...

Moody's Ratings (Moody's) has completed a periodic review of the ratings of Charles River Laboratories Int'l, Inc. and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 23 December 2025 in which we reassessed the appropriateness of the r...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

Back to Near-Term Bullish on SPX and QQQ We downgraded our near-term outlook on the S&P 500 (SPX) and Nasdaq 100 (QQQ) to neutral last week (11/19/25 Compass), after being bullish since our 4/22/25 Compass, while maintaining our intermediate-term bullish outlook (as of our 5/14/25 Compass). Crucial support levels of 6480-6520 on SPX and $580-$583 on QQQ held last week, and we are right back to being near-term bullish as long as these support levels continue to hold. Just know that SPX could see...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

6550-6569 S&P 500 Support Holding For Now After 5.5-months, the S&P 500 (SPX) has now failed to break and stay below the its 20-day MA. However, 6569 has been our level that needs to break in order for us to have confidence that a pullback has begun; SPX made a low of 6551 on Friday (less than 20 points or 0.3% from our 6569 level), meaning it was not a decisive breakdown (in time or price). As a result, our near-term bullish outlook since our 4/22/25 Compass remains intact, and it will stay t...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch